Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 04, 2020 08:00 ET | Source: Diasome Pharmaceuticals, Inc.

Diasome to Present at the Solebury Trout Summer 2020 Private Company Showcase

CLEVELAND, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
July 28, 2020 08:00 ET | Source: Diasome Pharmaceuticals, Inc.

Diasome to Present at the LifeSci Partners Summer Symposium

CLEVELAND, July 28, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
June 15, 2020 08:00 ET | Source: Diasome Pharmaceuticals, Inc.

Diasome Announces Substantial Reductions in Level 2 Hypoglycemia Events in its Phase 2b OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes

CLEVELAND, June 15, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
June 04, 2020 08:00 ET | Source: Diasome Pharmaceuticals, Inc.

Diasome to Present Data from Phase 2 OPTI-1 Clinical Trial at the 80th Annual American Diabetes Association Virtual Scientific Sessions

CLEVELAND, June 04, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
February 18, 2020 08:00 ET | Source: Diasome Pharmaceuticals, Inc.

Diasome Announces Positive Results from Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes

CLEVELAND, Feb. 18, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin...
February 12, 2020 08:00 ET | Source: Diasome Pharmaceuticals, Inc.

Diasome to Present Additional Data on Hepatocyte Directed Vesicle Technology in Type 1 Diabetes at the Advanced Technologies & Treatment for Diabetes International Conference

CLEVELAND, Feb. 12, 2020 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., today announced an upcoming ePoster presentation highlighting additional results from the Phase 2b InSulin Liver Effect-1...
December 10, 2019 10:00 ET | Source: Diasome Pharmaceuticals, Inc.

Diasome Appoints Dr. Jeremy Pettus as Chairman of Scientific Advisory Board

CLEVELAND, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals today named Dr. Jeremy Pettus the chairman of the company’s scientific advisory board. Dr. Pettus is a board-certified...
November 26, 2019 08:00 ET | Source: Diasome Pharmaceuticals, Inc.

Diasome Pharmaceuticals to Participate in the Piper Jaffray 31st Annual Healthcare Conference

CLEVELAND, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any insulin to improve blood...
September 24, 2019 10:51 ET | Source: Diasome Pharmaceuticals, Inc.

Diasome Announces Publication of Phase 2b Results in Diabetes Care

CLEVELAND, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals today announced the online publication of its InSulin Liver Effect (ISLE-1) Phase 2b study results in respected...
June 25, 2019 10:04 ET | Source: Diasome Pharmaceuticals, Inc.

Diasome Announces Completion of Enrollment in Phase 2 OPTI-1 Study of Hepatocyte Directed Vesicle Technology in Type 1 Diabetes

CLEVELAND, June 25, 2019 (GLOBE NEWSWIRE) -- Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any insulin to improve blood...